Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 203 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR How Does CAR T-Cell Therapy Work in Treating Cancer? June 17, 2021 Immunotherapy before Surgery Appears Effective for Some with Melanoma October 12, 2022 COVID-19 Vaccines: Considerations for Special Populations February 4, 2021 Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... July 4, 2024 Load more HOT NEWS Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical...
